Understanding Molecular Differences in Myeloid Neoplasms

The landscape of myeloid neoplasms is evolving rapidly due to advanced genomic profiling. Furthermore, recent studies have highlighted distinctive MDS molecular risk factors that separate Myelodysplastic Syndromes (MDS) from the newly defined MDS/AML category. Specifically, the International Consensus Classification (ICC) now classifies cases with 10% to 19% blasts as MDS/AML to reflect their aggressive clinical nature. Consequently, clinicians must look beyond blast counts. However, they should also focus on individual mutational profiles for accurate prognosis. Indeed, this approach ensures better patient outcomes.

Moreover, the International Prognostic Scoring System Molecular (IPSS-M) has significantly improved how we evaluate patients. In addition, this model integrates clinical parameters with genetic data. Therefore, it provides a more granular risk assessment. Specifically, mutations in genes like TP53, ASXL1, and SRSF2 play a pivotal role in determining survival outcomes. While MDS and MDS/AML share many genetic features, the impact of these mutations differs across the blast percentage spectrum. As a result, molecular data is now critical for routine diagnosis.

Incorporating MDS Molecular Risk Factors into Practice

Furthermore, identifying these genetic markers is essential for personalized medicine in hematology. For instance, TP53 mutations often signal a very high risk, regardless of whether a patient is classified as MDS or MDS/AML. Similarly, the presence of myelodysplasia-related mutations helps distinguish these cases from other myeloid conditions. Thus, incorporating molecular testing is no longer optional but a necessity for modern diagnostic workflows. Finally, these insights help physicians choose the most effective therapies for their patients.

Frequently Asked Questions

What is the main difference between MDS and MDS/AML in the ICC?

The primary difference lies in the bone marrow blast percentage. The ICC defines MDS/AML as having 10% to 19% blasts, whereas MDS typically involves lower blast counts. This category acknowledges the biological continuum and aggressive nature of these cases.

How does the IPSS-M improve patient care?

The IPSS-M improves care by using molecular data to re-stratify patients who might have been misclassified by older clinical systems. Consequently, this allows for more targeted treatment strategies and better prediction of leukemia transformation.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Zhang TJ et al. Distinctive Molecular Risk Factors Between MDS and MDS/AML Defined by ICC. Am J Hematol. 2026 Mar 30. doi: 10.1002/ajh.70296. PMID: 41913093.

Hasserjian RP et al. The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Arch. 2023 Jan;482(1):39-51. doi: 10.1007/s00428-022-03417-1.